FDA extends shelf life of COVID-19 treatment for hospitalized adults
The Food and Drug Administration recently extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab), authorized for emergency use to treat COVID-19 in certain hospitalized adults. The six-month extension applies to all retained product held in accordance with storage conditions detailed in the fact sheet for health care providers.
Related News Articles
Headline
CDC issues reminder on ending of the emergency authorization for COVID-19 in vitro diagnostics tests
The Centers for Disease Control and Prevention issued a reminder Oct. 14 that the declaration supporting the emergency use of COVID-19 in vitro diagnostics…
Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…